Amicus Therapeutics, Inc.
FOLD
Rang în acțiuni
#3689
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Preț acțiune
$14.49
Ultima sincronizare: 2026-04-27
Capitalizare de piață
$4.55B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
71.68%
Țară
US
Tranzacționează Amicus Therapeutics, Inc. (FOLD)
Categorie
Healthcare
Câștiguri pentru Amicus Therapeutics, Inc. (FOLD)
Câștiguri în Dec 2025 TTM: $191.00K
Conform celor mai recente rapoarte financiare ale Amicus Therapeutics, Inc., câștigurile actuale ale companiei sunt $191.00K. În anul 2023, compania a înregistrat un câștig de $-150.10M, o creștere față de câștigului din 2022, care a fost de $-242.04M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Amicus Therapeutics, Inc. din 2003 până în 2026
Câștiguri la sfârșitul fiecărui an
| An | Câștiguri | Schimbă |
|---|---|---|
| 2026 (TTM) | $191.00K | -100.66% |
| 2024 | $-28.76M | -80.84% |
| 2023 | $-150.10M | -37.98% |
| 2022 | $-242.04M | 0.20% |
| 2021 | $-241.55M | -11.92% |
| 2020 | $-274.25M | -22.94% |
| 2019 | $-355.91M | 1.95% |
| 2018 | $-349.09M | -22.27% |
| 2017 | $-449.12M | 120.39% |
| 2016 | $-203.78M | 54.24% |
| 2015 | $-132.12M | 88.63% |
| 2014 | $-70.04M | 10.92% |
| 2013 | $-63.15M | 21.36% |
| 2012 | $-52.03M | 8.30% |
| 2011 | $-48.04M | -14.33% |
| 2010 | $-56.08M | 753.89% |
| 2009 | $-6.57M | -83.31% |
| 2008 | $-39.36M | -4.40% |
| 2007 | $-41.17M | -11.17% |
| 2006 | $-46.34M | 125.15% |
| 2005 | $-20.58M | 0.00% |
| 2004 | 0.00 | -100.00% |
| 2003 | $-6.77M | 0.00% |
Câștiguri pentru companii similare sau concurente
| Companie | Câștiguri | Diferență de câștiguri | Țara |
|---|---|---|---|
| $5.27B | 2,761,627.75% |
US
|
|
| $-3.09B | -1,616,330.37% |
US
|
|
| $-4.02B | -2,102,820.66% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,021,182.77% |
NL
|
